BRIDGE CAR T™
Building Bridges Between Treatment Centers and Community Oncologists to Overcome Barriers in CAR T-Cell Therapy - The Lymphoma Edition
CAR-T cell therapy: from the shop to cancer therapy
Uscanga-Palomeque AC, et al. Int J Mol Sci. 2023;24(21):15688.
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell KM, Kochenderfer JN. Nat Rev Clin Oncol. 2023;20(6):359-371.
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Amini L, et al. Nat Rev Clin Oncol. 2022;19(5):342-355.
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Hayden PJ, et al. Ann Oncol. 2022;33(3):259-275.
Who is eligible for chimeric antigen receptor T cell therapy? Expert perspectives on overcoming referral barriers
Shadman M, et al. Transplant Cell Ther. 2026;32(3):277-287.
Bispecific antibodies versus chimeric antigen receptor T‐cell therapy in relapsed/refractory diffuse large B‐cell lymphoma: a comparative narrative review of efficacy, safety, and accessibility
Abou DS, et al. Cancer Med. 2026;15(2):e71562.
Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma
Hoffmann MS, et al. Transplant Cell Ther. 2023;29(7):440-448.
Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy
Beaupierre A, et al. J Adv Pract Oncol. 2019;10(suppl 3):29-40.
Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies
Kampouri E, et al. Transpl Infect Dis. 2023;25(suppl 1):e14157.
CRS and ICANS in CAR T-cell therapy for large B-cell lymphoma
Goto H. J Clin Exp Hematop. 2025;65(4):268-275.
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Sesques P, et al. J Hematol Oncol. 2024;17:61.
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
Yang Y, et al. Exp Hematol Oncol. 2024;13:110.
Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies
Shahid Z, et al. Transplant Cell Ther. 2024;30(10):955-969.
DOWNLOADABLE RESOURCES
Patient Wallet Cards
Download and print these helpful patient wallet cards
CAR T Lymphoma Patient FAQ Sheet
Download this cheat sheet of patient frequently asked questions and answers
New York CAR T Therapy Clinician Guide
Download and print this Clinician Guide to CAR T Therapy
GUIDELINES
B-cell Lymphomas, version 4.2026
National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, version 2.2026
NCCN Clinical Practice Guidelines in Oncology
CLINICIAN RESOURCES
Lymphoma Research Foundation
FDA eliminates Risk Evaluation and Mitigation Strategies (REMS) for autologous chimeric antigen receptor (CAR) T cell immunotherapies
MEMORIAL SLOAN KETTERING (MSK) CELLULAR THERAPY RESOURCES TO HELP PATIENTS UNDERGOING CAR T-CELL THERAPY
Insurance and financial assistance
- Social workers and patient financial navigators provide available financial resources
- Dedicated case managers for patient financial services provide insurance authorization coordination
Caregiver support
- Caregiver resource library: educational materials, dedicated video for caregivers
- Formalized Caregiver Clinic through MSK (https://www.mskcc.org/experience/caregivers-support)
Addressing socioeconomic barriers
- Social workers and patient financial navigators provide screening and interventions with available financial, travel, and meal support
Lodging and transportation
- Dedicated residence for cellular therapy patients (75th Street Housing)
- Travel vouchers available for some patient travel support
- MSK-arranged discounted hotel partnerships for patients and caregivers
Community transportation resources
(Air travel assistance)
- Transportation resources are available through manufacturer-supported programs
Ground transportation
MSK Patient Travel Program
- Programs available through MSK
PATIENT EDUCATION RESOURCES
Patient Advocacy Group Education Resources
Blood & Marrow Transplant Information Network
IMPORTANT CONTACT INFORMATION
MSK Cellular Therapy Service Contacts
- MSK Cellular Therapy Service main phone number: 1-888-MSK-CART (1-888-675-2278)
- Referring provider team
Email:
-
New domestic patients, inquiries can be sent to: referapatient@mskcc.org
-
For international patients, please email: international@mskcc.org
Phone:
-
For clinicians (available 24/7): 646-677-7440
-
For self-referral: 646-926-0946
Fax: 646-227-2476
Self-referral link for patients: https://www.mskcc.org/experience/become-patient/appointment
Additional links:
- https://www.mskcc.org/departments/division-hematologic-malignancies/cellular-therapeutics
- https://www.mskcc.org/research-areas/topics/cell-based-therapy
Hours:
- David H. Koch Center: Monday-Friday, 8 am-6 pm
- Memorial Hospital: 24 hours/day, 7days/week
30
2026
NY Part 1: CAR T Cell Therapy in NHL
Coordination of Care Between Our Center and Yours
| Time: | 6:00 PM-7:00 PM ET |
| Venue: | Memorial Sloan Kettering Cancer Center |
| Location: | New York, New York |
| Faculty: | Lia Palomba, MD |
27
2026
NY Part 2: CAR T-Cell Therapy in NHL Subtypes
A Case-Based Workshop
| Time: | 6:00 PM-7:00 PM ET |
| Venue: | Memorial Sloan Kettering Cancer Center |
| Location: | New York, New York |
| Faculty: | Lia Palomba, MD |
25
2026
FL Part 1: CAR T Cell Therapy in NHL
Coordination of Care Between Our Center and Yours
| Time: | 6:00 PM-7:00 PM ET |
| Venue: | Moffitt Cancer Center |
| Location: | Tampa, Florida |
| Faculty: | Frederick Locke, MD |
22
2026
FL Part 2: CAR T-Cell Therapy in NHL Subtypes
A Case-Based Workshop
| Time: | 6:00 PM-7:00 PM ET |
| Venue: | Moffitt Cancer Center |
| Location: | Tampa, Florida |
| Faculty: | Frederick Locke, MD |
02
2026
CA Part 1: CAR T Cell Therapy in NHL
Coordination of Care Between Our Center and Yours
| Time: | 5:00 PM-6:00 PM PT |
| Venue: | UCSD - Moores Cancer Center |
| Location: | San Diego, CA |
| Faculty: | Ayad Hamdan, MD |
07
2026
CA Part 2: CAR T-Cell Therapy in NHL Subtypes
A Case-Based Workshop
| Time: | 5:00 PM-6:00 PM PT |
| Venue: | UCSD - Moores Cancer Center |
| Location: | San Diego, CA |
| Faculty: | Ayad Hamdan, MD |
